 |
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. Centers for Disease Control and Prevention
• News Briefs
Celera Diagnostics to Market Gene-Based HIV Test
December 12, 2002 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. Celera Diagnostics, an Alameda, Calif., venture supported by
Celera Genomics and Applied Biosystems Group, said it received
clearance from the U.S. Food and Drug Administration to market a
gene-based HIV test. The test is designed to detect mutations in
HIV that create resistance to certain drug treatments. Studies
have found that up to 78 percent of patients show resistance to
drugs used to treat HIV. Genetic testing is common for HIV
patients, but Celera Genomics Chief Executive Kathy Ordoņez said
Celera Diagnostics' test could help standardize the process. A
unit of Abbott Laboratories will distribute the system.
Back to other CDC news for December 12, 2002 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. Washington Post 12.12.02
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. |
E-Mail
Printer Friendly
Glossary
Share
